Home

Find out the latest news from international oncology congresses and stay at the forefront of clinical innovation and advances in lung cancer research. Each SPECIAL ISSUE – CONGRESS REPORT features informative summaries of key topics from lung cancer to come out of a major international oncology congress.

The memo inOncology Medical education series: keeping oncologists at the forefront of lung cancer research. memo – inOncology Special Issue Preceptorship reports summarise the latest in lung cancer research and treatments to come out of our sponsored Preceptorship meeting series. The Fundamentals of Designing Clinical Trials series arms oncologists with the information they need to plan and conduct an oncology trial.

 

Michael Duruisseaux gives an overview on the role of NRG1 gene fusion in the tumorigenesis of lung cancer, the clinical experience with targeted treatment and the importance of molecular testing with respect to NRG1 fusions.

memo – inOncology SPECIAL ISSUE
ESMO Congress report 2019
The latest findings in lung cancer to come out of the ESMO Congress held from 27thSeptember to 1st October in Barcleona!

Preceptorship Singapore

Basics of leadership in clinical research with a focus on lung cancer

Young Oncologist Preceptorship, 8th–10th December, 2017, Singapore

News

Springer is delighted to announce a new memo inOncology SPECIAL ISSUE congress report from this years ASCO!

Congress Report ESMO 2019
memo – inOncology SPECIAL ISSUE
Congress Report ESMO 2019
This report summarizes a selection of abstracts presented at ESMO 2019 in the areas of targeted therapy and immunotherapy for both non-small-cell and small-cell tumours of the lung.

 

 


Springer memo Preceptorship Cologne CoverPreceptorship Shanghai – Modern Management of Advanced Lung Cancer:
Immunotherapy & Targeted Agents
Springer and the Shanghai Pulmonary Hospital held the Lung Cancer International Preceptorship on the 28th-29th June 2018, in Shanghai, China. The overall topic was the modern management of advanced lung cancer: Immunotherapy & Targeted Agents

Access the report here


Expert interviews at ESMO 2019


Filippo de Braud explains what can be achieved with TRK inhibition in TRK-fusion-positive NSCLC, indirectly compares the performance of entrectinib to crizotinib in ROS1-positive disease and shares his opinion on the intracranial activity of entrectinib.


Michael Duruisseaux gives an overview on the role of NRG1 gene fusion in the tumorigenesis of lung cancer, the clinical experience with targeted treatment and the importance of molecular testing with respect to NRG1 fusions.


Stephen Liu on the latest insights in the field of ALK-targeted treatment in lung cancer, a recent update on the clinical evaluation of NRG1-directed therapies, as well as novel molecular targets for lung cancer treatment in the foreseeable future.


Ioannis Metaxas talks about the rationale for the evaluation of lurbinectedin in malignant pleural mesothelioma, the clinical results with lurbinectedin in patients with mesothelioma to date and other areas of lung cancer treatment in which lurbinectedin might prove useful in the future.